X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-18 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $69.34 | -6,825 | 9,485 | -42% | -$473,255 | ||||||
D | 2024-03-15 | ACLX | Arcellx, Inc. | Ware Olivia C | Dir | S - Sale+OE | $70.40 | -9,000 | 0 | -100% | -$633,582 | |||||
D | 2024-03-15 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $72.69 | -3,524 | 6,476 | -35% | -$256,160 | |||||
D | 2024-03-15 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $72.48 | -20,000 | 408,122 | -5% | -$1,449,628 | |||||
D | 2024-03-14 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $21.86 | -15,000 | 408,035 | -4% | -$327,942 | |||||
2024-03-14 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $34.60 | -93 | 81,363 | 0% | -$3,218 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Appelrouth Stewart | Dir | P - Purchase | $0.33 | +90,910 | 239,765 | +61% | +$30,000 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.33 | +75,758 | 716,455 | +12% | +$25,000 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Rodino Peter W III | COO, Secretary, Gen. Counsel | P - Purchase | $0.33 | +37,879 | 181,718 | +26% | +$12,500 | ||||||
M | 2024-03-13 | ADMA | Adma Biologics, Inc. | Elms Steve | Dir | S - Sale | $6.11 | -1,038,284 | 2,653,828 | -28% | -$6,339,418 | |||||
M | 2024-03-14 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $40.25 | -127,543 | 806,697 | -14% | -$5,133,263 | |||||
2024-03-13 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $108.54 | -15,000 | 11,797,969 | 0% | -$1,628,031 | ||||||
D | 2024-03-14 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $139.38 | -75,000 | 40,778 | -65% | -$10,453,418 | |||||
D | 2024-03-13 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale+OE | $140.33 | -23,200 | 29,512 | -44% | -$3,255,621 | |||||
D | 2024-03-13 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.14 | -3,000 | 7,507 | -29% | -$420,419 | |||||
DM | 2024-03-13 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $44.35 | -35,000 | 194,870 | -15% | -$1,552,075 | |||||
A | 2024-03-08 | VCEL | Vericel Corp | Flynn Sean C. | SVP, GC | S - Sale | $45.33 | -8,115 | 167 | -98% | -$367,853 | |||||
DM | 2024-03-12 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $10.74 | -50,000 | 1,204,179 | -4% | -$537,190 | |||||
2024-03-14 | CGTX | Cognition Therapeutics Inc | Ricciardi Lisa | CEO, Pres | P - Purchase | $1.75 | +5,700 | 291,345 | +2% | +$9,975 | ||||||
M | 2024-03-11 | KYMR | Kymera Therapeutics, Inc. | Atlas Venture Fund X, L.P. | 10% | S - Sale | $42.20 | -353,357 | 5,504,905 | -6% | -$14,912,376 | |||||
M | 2024-03-11 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $42.20 | -353,357 | 828,830 | -30% | -$14,912,376 | |||||
M | 2024-03-11 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.92 | +16,329 | 1,010,842 | +2% | +$14,951 | |||||
DM | 2024-03-12 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $41.96 | -20,000 | 156,558 | -11% | -$839,100 | |||||
DM | 2024-03-11 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $34.04 | -23,671 | 142,467 | -14% | -$805,652 | |||||
2024-03-11 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale | $44.71 | -7,874 | 949 | -89% | -$352,047 | ||||||
2024-03-11 | CDTX | Cidara Therapeutics, Inc. | Tari Leslie | CHIEF SCIENTIFIC OFFICER | S - Sale | $0.67 | -21,029 | 260,165 | -7% | -$14,085 | ||||||
2024-03-11 | CDTX | Cidara Therapeutics, Inc. | Sandison Taylor | Chief Medical Officer | S - Sale | $0.67 | -20,662 | 347,095 | -6% | -$13,839 | ||||||
2024-03-11 | CDTX | Cidara Therapeutics, Inc. | Ward Shane | COO, CLO | S - Sale | $0.67 | -20,473 | 198,770 | -9% | -$13,713 | ||||||
2024-03-11 | CDTX | Cidara Therapeutics, Inc. | Shah Preetam | CFO, CBO | S - Sale | $0.67 | -18,931 | 227,210 | -8% | -$12,680 | ||||||
D | 2024-03-12 | JSPR | Jasper Therapeutics, Inc. | Mahal Jeetinder Singh | COO | S - Sale+OE | $26.44 | -900 | 25,009 | -3% | -$23,792 | |||||
D | 2024-03-11 | RGEN | Repligen Corp | Kuriyel Ralf | SVP, R, D | S - Sale+OE | $193.73 | -3,517 | 24,260 | -13% | -$681,348 | |||||
DM | 2024-03-08 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale+OE | $140.04 | -1,800 | 29,512 | -6% | -$252,078 | |||||
DM | 2024-03-08 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.03 | -2,000 | 7,507 | -21% | -$280,053 | |||||
DM | 2024-03-11 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $77.15 | -3,947 | 61,174 | -6% | -$304,515 | |||||
DM | 2024-03-11 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $77.04 | -14,385 | 408,122 | -3% | -$1,108,263 | |||||
A | 2024-02-21 | CHRO | Chromocell Therapeutics Corp | Friedberg Ezra M | Dir | P - Purchase | $6.00 | +16,667 | 545,721 | +3% | +$100,002 | |||||
2024-03-11 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $170.95 | -50,000 | 3,303,144 | -1% | -$8,547,719 | ||||||
2024-03-11 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $170.95 | -50,000 | 3,303,144 | -1% | -$8,547,719 | ||||||
D | 2024-03-08 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $197.44 | -16,707 | 185,249 | -8% | -$3,298,632 | |||||
2024-03-11 | XFOR | X4 Pharmaceuticals, Inc | Taveras Arthur | Chief Scientific Officer | S - Sale | $0.88 | -14,235 | 234,301 | -6% | -$12,552 | ||||||
2024-03-11 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $0.88 | -49,678 | 765,068 | -6% | -$43,856 | ||||||
2024-03-11 | XFOR | X4 Pharmaceuticals, Inc | Mostafa Adam S. | CFO | S - Sale | $0.88 | -52,500 | 0 | -100% | -$46,347 | ||||||
2024-03-11 | XFOR | X4 Pharmaceuticals, Inc | Dibiase Mary | COO | S - Sale | $0.88 | -15,409 | 291,752 | -5% | -$13,591 | ||||||
2024-03-08 | SANA | Sana Biotechnology, Inc. | Yang Patrick Y | Dir | S - Sale | $9.45 | -25,000 | 149,250 | -14% | -$236,300 | ||||||
2024-03-07 | OTLK | Outlook Therapeutics, Inc. | Evanson Jeff | Chief Commercial Officer | P - Purchase | $0.42 | +62,484 | 808,459 | +8% | +$26,243 | ||||||
2024-03-08 | DBVT | Dbv Technologies S.A. | Tasse Daniel | CEO | P - Purchase | $0.83 | +17,094 | 17,094 | New | +$14,188 | ||||||
2024-03-07 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale | $45.00 | -1,634 | 1,400 | -54% | -$73,530 | ||||||
2024-03-08 | VCEL | Vericel Corp | Flynn Sean C. | SVP, GC | S - Sale | $45.33 | -8,115 | 167 | -98% | -$367,853 | ||||||
D | 2024-03-07 | TECH | Bio-Techne Corp | Nusse Roeland | Dir | S - Sale+OE | $76.98 | -10,400 | 43,097 | -19% | -$800,627 | |||||
D | 2024-03-08 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $99.05 | -544 | 9,267 | -6% | -$53,884 | |||||
D | 2024-03-06 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $11.73 | -61,319 | 1,108,524 | -5% | -$719,505 | |||||
M | 2024-03-06 | HLVX | Hillevax, Inc. | Kohli Aditya | Dir | S - Sale | $18.66 | -18,000 | 825,776 | -2% | -$335,872 | |||||
DM | 2024-03-06 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale+OE | $5.04 | -53,515 | 114,149 | -32% | -$269,682 | |||||
2024-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $37.43 | -272 | 81,456 | 0% | -$10,181 | ||||||
2024-03-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $37.43 | -181 | 43,680 | 0% | -$6,775 | ||||||
D | 2024-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $37.43 | -1,487 | 516,409 | 0% | -$55,658 | |||||
2024-03-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $37.43 | -600 | 92,850 | -1% | -$22,458 | ||||||
2024-03-06 | TWST | Twist Bioscience Corp | Banyai William | See Remark | S - Sale | $37.43 | -549 | 346,755 | 0% | -$20,549 | ||||||
2024-03-05 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $12.06 | -20,054 | 7,272,809 | 0% | -$241,805 | ||||||
D | 2024-03-05 | RGNX | Regenxbio Inc. | Pakola Steve | Chief Medical Officer | S - Sale+OE | $28.36 | -12,878 | 107,192 | -11% | -$365,220 | |||||
2024-01-30 | ALLO | Allogene Therapeutics, Inc. | Parker Geoffrey M. | CFO | P - Purchase | $3.60 | +190 | 819,590 | 0% | +$683 | ||||||
2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | Principal Accounting Officer | S - Sale | $3.43 | -7,727 | 123,318 | -6% | -$26,504 | ||||||
D | 2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Taylor Stacy L | SVP, GC | S - Sale+OE | $3.43 | -13,381 | 166,287 | -7% | -$45,963 | |||||
D | 2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $3.43 | -14,700 | 256,245 | -5% | -$50,439 | |||||
D | 2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale+OE | $3.44 | -29,390 | 327,415 | -8% | -$100,994 | |||||
2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Rubinstein Julie | Pres | S - Sale | $3.47 | -39,070 | 472,754 | -8% | -$135,764 | ||||||
2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Peterson Tycho | CFO | S - Sale | $3.44 | -15,456 | 531,553 | -3% | -$53,169 | ||||||
2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $3.43 | -48,673 | 2,576,701 | -2% | -$167,007 | ||||||
D | 2024-03-05 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale+OE | $3.44 | -12,991 | 248,290 | -5% | -$44,629 | |||||
2024-03-05 | TNYA | Tenaya Therapeutics, Inc. | Hoey Timothy | Chief Scientific Officer | S - Sale | $7.00 | -3,300 | 245,346 | -1% | -$23,101 | ||||||
2024-03-04 | ATRA | Atara Biotherapeutics, Inc. | Touchon Pascal | Pres, CEO | S - Sale | $0.72 | -24,844 | 1,910,652 | -1% | -$17,888 | ||||||
2024-03-04 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | EVP, Chief Sci., Tech Officer | S - Sale | $0.72 | -10,746 | 941,397 | -1% | -$7,737 | ||||||
2024-03-04 | ATRA | Atara Biotherapeutics, Inc. | Hyllengren Eric J | EVP, CFO | S - Sale | $0.72 | -6,679 | 674,319 | -1% | -$4,810 | ||||||
2024-03-04 | ATRA | Atara Biotherapeutics, Inc. | Henrich Jill | EVP, Global Head RA, Quality | S - Sale | $0.72 | -3,879 | 555,001 | -1% | -$2,793 | ||||||
D | 2024-03-04 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $1.26 | -38,826 | 808,125 | -5% | -$48,765 | |||||
D | 2024-03-05 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale+OE | $9.42 | -77,824 | 327,470 | -19% | -$732,884 | |||||
D | 2024-03-04 | EDIT | Editas Medicine, Inc. | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | S - Sale+OE | $9.42 | -20,327 | 141,543 | -13% | -$191,425 | |||||
2024-03-04 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $6.92 | -5,716 | 144,957 | -4% | -$39,562 | ||||||
2024-03-04 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $6.92 | -18,837 | 5,930,755 | 0% | -$130,386 | ||||||
2024-03-04 | ALEC | Alector, Inc. | Romano Gary | Chief Medical Officer | S - Sale | $6.92 | -6,001 | 196,313 | -3% | -$41,554 | ||||||
2024-03-04 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $6.92 | -10,169 | 318,847 | -3% | -$70,387 | ||||||
D | 2024-03-04 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $94.34 | -117 | 8,673 | -1% | -$11,038 | |||||
D | 2024-03-04 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $94.34 | -309 | 1,672,290 | 0% | -$29,151 | |||||
D | 2024-03-01 | BLUE | Bluebird Bio, Inc. | Colvin Richard A | Chief Medical Officer | S - Sale+OE | $1.53 | -6,770 | 118,368 | -5% | -$10,342 | |||||
D | 2024-03-04 | BLUE | Bluebird Bio, Inc. | Obenshain Andrew | Pres, CEO | S - Sale+OE | $1.53 | -6,095 | 279,998 | -2% | -$9,311 | |||||
D | 2024-03-04 | BLUE | Bluebird Bio, Inc. | Klima Thomas J | See Remarks | S - Sale+OE | $1.53 | -4,573 | 124,840 | -4% | -$6,986 | |||||
2024-03-04 | FATE | Fate Therapeutics Inc | Dulac Edward J III | CFO | S - Sale | $7.77 | -2,447 | 101,479 | -2% | -$19,013 | ||||||
D | 2024-03-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $73.71 | -3,000 | 218,674 | -1% | -$221,134 | |||||
D | 2024-03-01 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale+OE | $74.08 | -11,678 | 12,156 | -49% | -$865,070 | |||||
D | 2024-03-01 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $73.73 | -1,667 | 30,597 | -5% | -$122,907 | |||||
D | 2024-03-01 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $73.70 | -2,616 | 561,517 | 0% | -$192,799 | |||||
D | 2024-03-04 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Chief Medical Officer | S - Sale+OE | $41.86 | -3,344 | 95,740 | -3% | -$139,967 | |||||
D | 2024-03-04 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $41.86 | -3,934 | 142,351 | -3% | -$164,664 | |||||
D | 2024-02-28 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | Chief Accounting Officer | S - Sale+OE | $165.88 | -5,000 | 15,622 | -24% | -$829,417 | |||||
D | 2024-02-28 | KRYS | Krystal Biotech, Inc. | Romano Kathryn | Chief Accounting Officer | S - Sale+OE | $166.05 | -7,500 | 12,936 | -37% | -$1,245,381 | |||||
D | 2024-02-29 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $94.57 | -647 | 4,300 | -13% | -$61,188 | |||||
D | 2024-02-29 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $94.57 | -670 | 8,557 | -7% | -$63,363 | |||||
D | 2024-02-29 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $94.57 | -2,388 | 1,671,947 | 0% | -$225,838 | |||||
D | 2024-02-28 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $68.59 | -36,509 | 0 | -100% | -$2,504,158 | |||||
DM | 2024-02-28 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $135.34 | -6,817 | 7,507 | -48% | -$922,632 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |